Department of Pharmacology, Bombay College of Pharmacy, Mumbai 400098, India.
Department of Pharmacology, Bombay College of Pharmacy, Mumbai 400098, India.
Clin Immunol. 2021 Dec;233:108879. doi: 10.1016/j.clim.2021.108879. Epub 2021 Nov 16.
COVID-19 is a pandemic requiring immediate solution for treatment because of its complex pathophysiology. Exploration of novel targets and thus treatment will be life savers which is the need of the hour. 2 host factors- TMPRSS2 and ACE2 are responsible for the way the virus will enter and replicate in the host. Also NRF2 is an important protein responsible for its anti-inflammatory role by multiple mechanisms of action like inhibition of NF-kB, suppression of pro-inflammatory genes, etc. NRF2 is deacetylated by Sirtuins and therefore both have a direct association. Absence of SIRT indicates inhibition of NRF2 expression and thus no anti-oxidative and anti-inflammatory protection for the cell. Therefore, we propose that NRF2 activators and/or SIRT activators can be evaluated to check their efficacy in ameliorating the symptoms of COVID-19.
COVID-19 是一种大流行病，其复杂的病理生理学需要立即解决治疗方法。探索新的靶点和治疗方法将是拯救生命的关键，这是当前的迫切需求。2 个宿主因素-TMPRSS2 和 ACE2 负责病毒进入和在宿主中复制的方式。此外，NRF2 是一种重要的蛋白质，通过多种作用机制（如抑制 NF-kB、抑制促炎基因等）发挥抗炎作用。NRF2 被 Sirtuins 去乙酰化，因此两者有直接的关联。SIRT 的缺失表明 NRF2 表达受到抑制，因此细胞没有抗氧化和抗炎保护。因此，我们提出可以评估 NRF2 激活剂和/或 SIRT 激活剂，以检查它们在改善 COVID-19 症状方面的疗效。
